Login to Your Account



Pharma: Other News To Note


Friday, November 1, 2013
• Baxter International Inc., of Deerfield, Ill., said it submitted a marketing authorization application to the European Medicines Agency for Rixubis, (recombinant Factor IX [nonacog gamma]) to treat and prevent bleeding in patients with hemophilia B.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription